BACKGROUND: The anti-inflammatory drug etanercept may be an effective therapeutic agent in diabetic retinopathy. In order to further evaluate its potential, the pharmacokinetics and safety of this drug after intravitreal delivery were investigated. METHODS: After intravitreal administration of etanercept in rabbits, clinical examination, electroretinography (ERG), visually evoked potentials (VEP) and histology were evaluated. The pharmacokinetics and distribution of etanercept were analyzed using fluorescence-coupled protein at 0, 2, 4, and 8 weeks after injection in vitreous, retina, and choroid. RESULTS: No adverse effects and signs of toxicity were found. Etanercept showed peak concentrations after 4 weeks in the retina and choroid. CONCLUSIONS: Intravitreally delivered etanercept is safe and results in high concentrations in the retina and choroid over a long period of time.
BACKGROUND: The anti-inflammatory drug etanercept may be an effective therapeutic agent in diabetic retinopathy. In order to further evaluate its potential, the pharmacokinetics and safety of this drug after intravitreal delivery were investigated. METHODS: After intravitreal administration of etanercept in rabbits, clinical examination, electroretinography (ERG), visually evoked potentials (VEP) and histology were evaluated. The pharmacokinetics and distribution of etanercept were analyzed using fluorescence-coupled protein at 0, 2, 4, and 8 weeks after injection in vitreous, retina, and choroid. RESULTS: No adverse effects and signs of toxicity were found. Etanercept showed peak concentrations after 4 weeks in the retina and choroid. CONCLUSIONS: Intravitreally delivered etanercept is safe and results in high concentrations in the retina and choroid over a long period of time.
Authors: K Miyamoto; S Khosrof; S E Bursell; R Rohan; T Murata; A C Clermont; L P Aiello; Y Ogura; A P Adamis Journal: Proc Natl Acad Sci U S A Date: 1999-09-14 Impact factor: 11.205
Authors: Kan Koizumi; Vassiliki Poulaki; Sven Doehmen; Gerhard Welsandt; Sven Radetzky; Alexandra Lappas; Norbert Kociok; Bernd Kirchhof; Antonia M Joussen Journal: Invest Ophthalmol Vis Sci Date: 2003-05 Impact factor: 4.799
Authors: Isabel Pascual-Camps; Pablo Hernández-Martínez; Laura Monje-Fernández; Rosa Dolz-Marco; Roberto Gallego-Pinazo; Lihteh Wu; J Fernando Arévalo; Manuel Díaz-Llopis Journal: J Ophthalmic Inflamm Infect Date: 2014-10-15
Authors: Panagiotis G Theodossiadis; Vasilios S Liarakos; Petros P Sfikakis; Alexander Charonis; Georgios Agrogiannis; Nikolaos Kavantzas; Ioannis A Vergados Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-11-04 Impact factor: 3.117
Authors: Suk Ho Byeon; Oh W Kwon; Ji Hun Song; Sung Eun Kim; Yong Sik Park Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-08-06 Impact factor: 3.117